Resources for HCPs
Hear From an Expert
A leader in oncology weighs in on RYBREVANT®, a first-of-its-kind treatment option for patients with mNSCLC with EGFR exon 20 insertion mutations
RYBREVANT® NCCN Guidelines Flashcard
See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation for RYBREVANT®
RYBREVANT® Dosing and Administration Guide
Comprehensive dosing, dose modification, preparation, and administration for RYBREVANT®
RYBREVANT® Adverse Reactions Management Guide
A detailed look at potential adverse reactions that can occur during treatment with RYBREVANT®
RYBREVANT® Rash Management Guide
A step-by-step guide to help manage dermatologic adverse reactions that patients may experience during treatment
Testing and Treatment for EGFR Exon 20 Insertion Mutation+ mNSCLC
An overview of the NCCN Guidelines® recommendations for the testing and treatment of mNSCLC with EGFR exon 20 insertion mutations
Mechanism of Disease (MOD) Video
Learn what makes most EGFR exon 20 insertion mutations different
Janssen CarePath is your one source for access, affordability, and treatment support for your patients
Reference LabFact Sheet
Biomarker testing guidelines and a list of liquid and tissue NGS test providers
Resources for Patients
RYBREVANT® Prospective Patient Brochure
Getting patients started on their journey with RYBREVANT®
RYBREVANT® Patient Starter Kit Brochure
Helpful information for patients to manage their treatment
RYBREVANT® Patient Starter Kit Advocacy Flashcard
Organizations in the mNSCLC community that provide support during treatment
RYBREVANT® Patient Starter Kit Infusion Schedule Flashcard
An overview to help patients understand and prepare for their infusions during treatment
RYBREVANT® Patient Starter Kit Treatment Journal
A tool to help patients stay organized, prepare, and reflect during their treatment on RYBREVANT®
Information on insurance coverage, out-of-pocket costs, and treatment support
Janssen CarePath Savings Program for RYBREVANT®
Eligible commercially insured patients can save on their out-of-pocket medication costs for RYBREVANT®
Resources for Access & Affordability
RYBREVANT® Medicare Payment Policy Flashcard
Important information regarding Medicare's payment policy for RYBREVANT®
Coding & Billing Flashcard
An explanation for office staff about insurance codes and billing
How to order RYBREVANT® for your patients
Access andReimbursement Guide
A helpful guide to navigating access for RYBREVANT®
Sample Letter of Medical Necessity (LMN)
An editable LMN template to use either with an initial claim or when requesting reconsideration for a denied claim
Sample Exception Letter
A template exception letter to use when requesting an exception for RYBREVANT®
Lung Cancer Communities and Organizations
The EGFR Resisters is a group of people living with and/or personally affected by EGFR-positive lung cancer.
Exon 20 Group
Patients and their families are welcome to join the Exon 20 Group. Membership is free of charge.
The GO2 Foundation for Lung Cancer
Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
Lung Cancer Foundation of America (LCFA)
LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.
LUNGevity is the largest national lung cancer-focused nonprofit. They are committed to changing the outcomes for people with lung cancer through research, education, and support.
These groups and foundations are not affiliated with Janssen Biotech, Inc. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by Janssen Biotech, Inc., or any groups or foundations referenced herein.
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson. Patients may be eligible if they don’t have insurance, if their medicine is not covered by insurance, or if they have Medicare coverage and can’t pay for their medicine.
Do you have patients who may need help? They can see if they are eligible and get an application at JJPAF.org or call 833-919-3510 (toll free) / 308-920-4358 (direct dial), Monday through Friday, 9:00 AM to 6:00 PM ET.